Einstellung von Patienten mit entzündlich-rheumatischen Erkrankungen zur immunsuppressiven Therapie im Rahmen der COVID-19 Pandemie – eine Situationsanalyse

Schmeiser, Tim; Broll, Matthias; Dormann, Arno J.; Fräbel, Christian; Hermann, W.; Hudowenz, Ole; Keil, Ferdinand; Müller‐Ladner, Ulf; Özden, Fatih; Pfeiffer, Ulrich J.; Saech, Jasemine; Schwarting, Andreas; Stapfer, G.; Steinchen, Nicolai; Storck-Müller, K.; Strunk, J.; Thiele, Astrid; Triantafyllias, K.; Wassenberg, S; Wilden, Elke; Hasseli, Rebecca

doi:10.1007/s00393-020-00800-8

Cited by 12 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher fear levels seem to be associated with comorbidity burden. But fear does not seem to increase therapy change, because unauthorized change of immunosuppressive medication was rare in our study (5%) as seen in most other studies (2.2%, 3.8%, 1%) [ 2 – 4 ]. These low rates of unauthorized changes and high rates of compliance are reassuring since good disease control appears to be prognostically important in the progression of COVID-19 disease.…”

Section: Discussionsupporting

confidence: 51%

See 1 more Smart Citation

Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey

Dahm

Henes²,

Saur³

2023

Rheumatol Int

View full text Add to dashboard Cite

This study provides insight in behavior and perspective of rheumatic patients during the first COVID-19 wave. Especially, we analyzed the patients’ fear of COVID-19 and unauthorized change of immunosuppressive medication in consequence of their fear. We hereby provide data from 877 patients with valuable insights into the patients’ point of view. We retrospectively interviewed patients of our rheumatic university outpatient clinic. This way, we collected information about the patients’ personal point of view. Data like the rheumatic diagnosis and immunosuppressive medication was extracted from the health records. Statistical analysis was conducted using IBM® SPSS® Statistics (version 26). A total of 877 patients were included into our study. We could show that fear of COVID-19 was clearly present in rheumatic patients. Higher fear levels seem to be associated with comorbidity burden. Unauthorized change of immunosuppressive medication was rare in our study (5%). In our study we provide novel insight into patients’ point of view and behavior of rheumatic patients. Unauthorized change of immunosuppressive medication was rare (5%) as seen in other studies. The low rate of unauthorized change and high rate of compliance is reassuring since good disease control appears to be prognostically important in the progression of COVID-19 disease. Therefore, as the pandemic continues, treatment decisions should be made in close consultation between patient and practitioner to improve adherence and reduce morbidity and mortality.

show abstract

Section: Discussionsupporting

confidence: 51%

“…Coherently, a majority of 90% followed the recommendation to maintain their medication. An unauthorized stop of the medication was observed in 1% of the patients and 4% said they would like to stop their medication but followed the practitioner’s advice to maintain it [ 4 ]. A study with similar focus as ours came to interesting results.…”

Section: Discussionmentioning

confidence: 99%

Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey

Dahm

Henes²,

Saur³

2023

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…Over 90% of the patients followed the recommendation of the rheumatologists to continue the antirheumatic therapy, and only a small percentage of patients terminated the therapy on their own. 6 Whether first recommendations based on responsible care and expert's opinion is indeed the best option for the management of patients with IRD urgently needs to be validated.…”

Section: How Might This Impact On Clinical Practice?mentioning

confidence: 99%

National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD

Hasseli

Müeller-Ladner

Schmeiser³

et al. 2020

RMD Open

View full text Add to dashboard Cite

ObjectivesPatients with inflammatory rheumatic diseases (IRD) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to develop a severe course of COVID-19. The influence of immunomodulating drugs on the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2 infections in patients with IRD, we established a registry shortly after the beginning of the pandemic in Germany.MethodsUsing an online questionnaire (www.COVID19-rheuma.de), a nationwide database was launched on 30 March 2020, with appropriate ethical and data protection approval to collect data of patients with IRD infected with SARS-CoV-2. In this registry, key clinical and epidemiological parameters—for example, diagnosis of IRD, antirheumatic therapies, comorbidities and course of the infection—are documented.ResultsUntil 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2 were reported (40 males; 63 females; 1 diverse). Most of them (45%) were diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42% were treated with biological disease-modifying antirheumatic drugs. Hospitalisation was reported in 32% of the patients. Two-thirds of the patients already recovered. Unfortunately, 6 patients had a fatal course.ConclusionsIn a short time, a national registry for SARS-CoV2-infected patients with IRD was established. Within 4 weeks, 104 cases were documented. The registry enables to generate data rapidly in this emerging situation and to gain a better understanding of the course of SARS-CoV2-infection in patients with IRD, with a distinct focus on their immunomodulatory therapies. This knowledge is valuable for timely information of physicians and patients with IRD, and shall also serve for the development of guidance for the management of patients with IRD during this pandemic.

show abstract

“…Over 90% of the patients confirmed that they would continue the treatment even during the COVID-19 pandemic. In addition, most of them (56%) had rheumatoid arthritis [22]. The individual patient's decision to continue DMARD therapy reflects the trusting relationship between patients and their doctors.…”

Section: Discussionmentioning

confidence: 99%

Treatment Adherence of Patients with Rheumatoid Arthritis during COVID-19 Pandemic

Bandyopadhyay¹,

Mondal²

2021

OJRA

View full text Add to dashboard Cite

India is no exception to the economic setback due to coronavirus disease 2019 . Loss of jobs and income dramatically impacts the health care cost of chronic disease management. Rheumatoid arthritis is a chronic condition with a high-cost implication. With the outbreak of COVID-19, there is uncertainty about continuing immunosuppressive therapy for rheumatoid arthritis for several reasons. In this milieu, we undertook a prospective observational study to observe the use of Janus Kinase (JAK) inhibitors in a hospital-based rheumatology service in Eastern India during the pandemic period (21 March 2020 to 31 July 2020). Forty-two patients with rheumatoid arthritis were receiving treatment with JAK inhibitors. Twenty-four patients visited the Outpatient Department (OPD) during the COVID-19 pandemic. All of them were COVID-negative, but few of the patients had influenza-like symptoms. Patients faced up to a 25% reduction in their annual income during the COVID-19 pandemic. Of 24 patients, four patients had stopped treatment with JAK inhibitors owing to financial constraints or initial non-availability of medications during the lockdown. In this study, adherence to JAK inhibitors was substantially high even in the face of income curtailment during the COVID-19 pandemic.

show abstract

Einstellung von Patienten mit entzündlich-rheumatischen Erkrankungen zur immunsuppressiven Therapie im Rahmen der COVID-19 Pandemie – eine Situationsanalyse

Cited by 12 publications

References 7 publications

Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey

Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey

National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD

Treatment Adherence of Patients with Rheumatoid Arthritis during COVID-19 Pandemic

Contact Info

Product

Resources

About